Cellestia Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
Cellestia General Information
Description
Developer of drugs and therapeutics intended to reach breakthroughs in cancer treatments and therapies that will lead to a cure for previously incurable cancers. The company develops targeted therapies built on a unique mode of action of targeting protein-protein interactions with small molecules to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus, enabling healthcare companies to pursue an integrated approach by combining drug and personalized medicine development for patient selection.
Contact Information
Website
www.cellestia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Technology Park Basel
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Cellestia Timeline
Cellestia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Secondary Transaction - Private | 28-Jun-2023 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 9. Later Stage VC (Series C) | 17-Aug-2021 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 8. Later Stage VC (Series B) | 17-Dec-2019 | 0000 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 7. Grant | 01-Jan-2019 | 0000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 6. Early Stage VC (Series A) | 20-Dec-2018 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 5. Seed Round | 10-Apr-2018 | 00.000 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 4. Seed Round | 28-Mar-2016 | 000.00 | Completed | Startup | ||
| 3. Grant | 00.000 | 000.00 | Completed | Startup | ||
| 2. Debt - General | 26-Jun-2015 | $32.1K | $32.1K | Completed | Startup | |
| 1. Seed Round | 01-May-2014 | Completed | Startup |
Cellestia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 0,000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
| Ordinary | 0,000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
| Ordinary | 000,000 | 00.00 | 00.00 | 00 | 00.00 | 000 | ||
| Ordinary | 346,341 | $6.65 | $6.65 | 1x | $6.65 | 7.09% | ||
| Ordinary | 83,473 | $6.04 | $6.04 | 1x | $6.04 | 1.71% |
Cellestia Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of drugs and therapeutics intended to reach breakthroughs in cancer treatments and therapies that will lead to
Drug Discovery
Basel, Switzerland
15
As of 2023
000.00
00000000000
000.00
000000
in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
0000 000000000
Cambridge, United Kingdom
000
As of 0000
00000
0000
0000-00-00
00000000000
00000
000000
m veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commod
0000 000000000
Stamford, CT
000
As of 0000
00000
000000 - 000
00000
Add Comparison
Cellestia Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Artios | Venture Capital-Backed | Cambridge, United Kingdom | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 000000 | Formerly VC-backed | Stamford, CT | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Wilmington, DE | 00 | 00000 | 000000&0 | 00000 |
| 000000 000 | Venture Capital-Backed | Abingdon, United Kingdom | 00 | 00000 | 0000000000 0 | 00000 |
| 000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
Cellestia Patents
Cellestia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4223292-A1 | Pharmaceutical combinations for treating cancer | Pending | 07-Feb-2022 | 000000000 | 00 |
| EP-4255409-A1 | Pharmaceutical combinations for treating cancer | Pending | 07-Dec-2020 | 0000000000 | |
| EP-4008324-A1 | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer | Inactive | 07-Dec-2020 | 0000000000 | 00 |
| EP-4213845-A1 | New use of inhibitors of the notch signalling pathway | Pending | 16-Sep-2020 | 00000000000 | |
| US-20230338347-A1 | New use of inhibitors of the notch signalling pathway | Pending | 16-Sep-2020 | A61K31/4412 |
Cellestia Executive Team (10)
Cellestia Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Epstein | Self | Board Member | 000 0000 |
| Guido Guidi MD | Self | Chairman | 000 0000 |
| Karen Chu Ph.D | Self | Board Member | 000 0000 |
| Rajwinder Lehal Ph.D | Cellestia | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| Robert Karsunky | Self | Board Member | 000 0000 |
Cellestia Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cellestia Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bernina BioInvest | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Hemex (Consulting Services (B2B)) | VC-Backed Company | Minority | 000 0000 | 000000 0 | |
| SNGLR Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| The Invus Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| T-Life Capital | Venture Capital | Minority | 000 0000 | 000000 0 |